For: | Yamashita Y, Tsujino I, Sato T, Yamada A, Watanabe T, Ohira H, Nishimura M. Hemodynamic effects of ambrisentan-tadalafil combination therapy on progressive portopulmonary hypertension. World J Hepatol 2014; 6(11): 825-829 [PMID: 25429321 DOI: 10.4254/wjh.v6.i11.825] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v6/i11/825.htm |
Number | Citing Articles |
1 |
Lynn A. Fussner, Michael J. Krowka. Current Approach to the Diagnosis and Management of Portopulmonary Hypertension. Current Gastroenterology Reports 2016; 18(6) doi: 10.1007/s11894-016-0504-2
|
2 |
M. Cataldi, A. Cavaccini. Reference Module in Biomedical Sciences. 2017; doi: 10.1016/B978-0-12-801238-3.99354-1
|
3 |
Masanori Atsukawa, Masashi Takano, Junichi Omura. Treatment pattern and clinical outcomes in portopulmonary hypertension: A database study in Japan. JGH Open 2022; 6(11): 763 doi: 10.1002/jgh3.12820
|
4 |
Arun Jose, Shimul A. Shah, Chandrashekar J. Gandhi, Francis X. McCormack, Jean M. Elwing. Orphan Lung Diseases. 2023; : 177 doi: 10.1007/978-3-031-12950-6_11
|
5 |
Michael McGee, Nicholas Whitehead, Scott Twaddell, Nicholas Collins. Pulmonary hypertension in patients with a history of intravenous drug use. Current Medical Research and Opinion 2019; 35(6): 1097 doi: 10.1080/03007995.2018.1558863
|